NewCures is Northwestern University’s biomedical accelerator focusing on the development of potential therapeutic technologies from University laboratories. Our mission is to enhance and strengthen Northwestern’s therapeutic pipeline before licensing and ultimately to expedite the translational process of early-stage research discoveries into next generation medical treatments. NewCures supports projects through pre-clinical stages, in particular, proof-of-concept validation and pharmacological de-risking. By aligning with industry standards, NewCures fills a translational gap in therapeutic development and aims to enhance and de-risk discoveries by:

(1) identifying potential assets in faculty laboratories;
(2) providing expertise and resources to formulate a strategic, project-specific development plan;
(3) developing robust, validated preclinical data; and
(4) translating research to industry-ready assets to attract external partnerships and investment from the private sector.

Contact Information
NewCures@northwestern.edu

Key Dates
Applications due: October 22, 2018
Selection decision: January, 2019
**Area of Interest**
All molecular-based therapeutic projects with an identified biological target with a translational/commercialization trajectory are encouraged to apply. At this time, NewCures does **not** support projects involving therapeutic delivery/formulation, diagnostics, devices, research tools or healthcare information.

**Eligibility**
**Applicant:** Northwestern University principal investigator (PI) with a full-time faculty appointment.

**Intellectual property (IP)**\(^1\) related to the application must meet the following criteria:
- Owned by Northwestern University;
- If IP is jointly owned, NU must be the lead, and joint owner must be a non-profit organization;
- Should cover Composition of Matter (issued or pending);
- Preference for international protection (issued or pending); and
- Not licensed to a third party.

\(^1\)If IP has not been disclosed to INVO, please contact INVO and NewCures to discuss. All projects must be reviewed for IP protection by INVO to be considered. The invention disclosure process is on INVO website ([http://www.invo.northwestern.edu](http://www.invo.northwestern.edu)).

**Funding/Benefits**
Projects will be supported at a level deemed necessary to achieve carefully evaluated objectives. After project selection and PI agreement, NewCures will:
- Work with the PI and external experts to formulate a development plan, outlining key pre-clinical experiments for proof-of-concept validation;
- Execute milestone-driven project plans (i.e., data collection), which will mainly consist of outsourcing experimental work to third party contract research organizations (CROs) – outsourced work will be managed and paid for by NewCures (up to $200K)\(^2\); and
- Work with INVO and the PI to engage potential private sector partnership and/or investment, contingent on the achievement of desired experimental outcomes/milestones.

\(^2\)NewCures serves the role of project manager and makes direct payments to the CROs. NewCures does not provide direct funding to the PI’s chartstring.
Evaluation Criteria

The goal of NewCures Accelerator is to advance molecular-based technologies to the point where technology transfer is achieved or additional funding/partnership is secured from the private sector. Thus, applications will be evaluated on overall potential for technology transfer, including scientific/technical merit, unmet medical need and commercial potential.

Please refer to Table 1 for a list of evaluation criteria for project review. The gaps identified will be noted as potential areas of support by NewCures once the project is selected for NewCures development processes. Importantly, NewCures does not expect that submitted projects will have the data/information to support all criteria listed below.

Table 1. Example list of criteria for NewCures Review and Development

<table>
<thead>
<tr>
<th>Target Validation</th>
<th>Evidence of target engagement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assessment of off-target activity</td>
</tr>
<tr>
<td>Scientific Rationale</td>
<td>Mechanism of action</td>
</tr>
<tr>
<td></td>
<td>Biological Data/Efficacy</td>
</tr>
<tr>
<td></td>
<td>- In Vitro</td>
</tr>
<tr>
<td></td>
<td>- In Vivo animal data</td>
</tr>
<tr>
<td>Safety Demonstration</td>
<td></td>
</tr>
<tr>
<td>Novelty of Composition</td>
<td>Screening of Hit-to-Lead</td>
</tr>
<tr>
<td></td>
<td>Identification of lead compound</td>
</tr>
<tr>
<td>Drug-like Properties</td>
<td>Pharmacokinetics/Pharmacodynamics</td>
</tr>
<tr>
<td></td>
<td>Protein binding</td>
</tr>
<tr>
<td></td>
<td>Metabolic stability</td>
</tr>
<tr>
<td>Attractiveness of Indication</td>
<td>Potential impact and significance for patients</td>
</tr>
<tr>
<td></td>
<td>Market need and opportunity</td>
</tr>
</tbody>
</table>
APPLICATION DIRECTIONS

Send single PDF file to newcures@northwestern.edu by 5:00 PM CST on October 22, 2019. Filename format: “Lastname_newcures.pdf”

Prepare a project description (1 title page, 2 project pages including figures and references, 11-point font, 1” margins) as follows:

Title Page (1 page)
1. PI name and affiliation
2. Project title
3. Project team (if applicable): name, affiliation and area of expertise of the research scientists
4. Project area: small molecules, biologics, gene therapy, protein therapy, cell therapy, others
5. Intellectual property: list if there are patents covering the project or invention disclosures with INVO, i.e., Northwestern reference number
6. All prior, current and pending sources of support related to the application
7. IRB/IACUC approval number (if applicable)
8. Non-confidential executive summary (≤ 150 words), which may be shared with industry partners with permission from the PI: describe the biomedical need or opportunity and the significance of the proposed technology; state the major research findings and how they will advance therapeutic potential; describe the potential commercial market for the technology

Project Pages (2 pages)
A. Project description and clinical need
   Summary of the project including:
   i. Scientific merit and significant findings
   ii. Current stage of development
   iii. Description of the medical need and desired indication
B. Competitive landscape
   Brief description of the current standard of care and how the potential therapeutic of this project, if developed, will be an improvement over currently available treatment
C. Project needs
   Briefly summarize the resources and expertise that are needed to progress the project towards drug development with an estimated cost. Please note
NewCures does **not** provide funding towards personnel, equipment, materials or reagents.

**Review Process**
Each application will be judged on the basis of translational and commercialization potential, scientific merit, and medical need.

Applications will be initially reviewed for basic eligibility and feasibility, followed by a review and prioritization by NewCures and INVO team members experienced in therapeutic technology assessment and development. **NewCures may request for additional data and information during the prioritization process.** Prioritized applications will be presented to NewCures Board of Advisors for final selection.

To ensure a thorough selection process, the NewCures Advisory Board consisting of members from within and outside of the Northwestern community will collectively review the applications. Internal members are leaders from Northwestern scientific communities with experience in therapeutic translation. External members are highly recognized leaders with expertise in therapeutic development from pharmaceutical, biotech and investment communities; all external members will have signed confidentiality agreement with Northwestern. To avoid potential conflict of interest, Northwestern-affiliated board members will not have voting rights to determine which projects will be supported by NewCures. Only external members will be involved in the final selection of NewCures projects.

**Project Execution and Management**
NewCures project team will work with the PI, external consultants and subject matter experts to develop a pre-clinical development plan for the technology. The experimental work will be coordinated and managed by NewCures, either through internal resources (Northwestern Core Facilities) or third party CROs.

NewCures will work with the PI to generate a “pitch deck” to facilitate NewCures and INVO to engage the private sector for potential licensing, collaboration and/or investment.
NOTE
NewCures is dedicated to foster ongoing molecular-based therapeutic technology development at Northwestern. For the applications that are not accepted this round, NewCures will continue to engage and interact with PIs to provide guidance and support, as needed, for future development.

FAILURE TO FOLLOW THESE INSTRUCTIONS WILL RESULT IN THE APPLICATION BEING RETURNED WITHOUT REVIEW.

Please do not include appendices.

APPLICATION DEADLINE: MONDAY, OCTOBER 22, 2018, 5:00 PM CST
NewCures@northwestern.edu